See more : Summit Securities Limited (SUMMITSEC.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Odyssey Group International, Inc. (ODYY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odyssey Group International, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Shenzhen Everwin Precision Technology Co., Ltd. (300115.SZ) Income Statement Analysis – Financial Results
- SpectraScience, Inc. (SCIE) Income Statement Analysis – Financial Results
- Diamond Power Infrastructure Limited (DIACABS.NS) Income Statement Analysis – Financial Results
- Autohome Inc. (ATHM) Income Statement Analysis – Financial Results
- Iota Communications, Inc. (IOTC) Income Statement Analysis – Financial Results
Odyssey Group International, Inc. (ODYY)
About Odyssey Group International, Inc.
Odyssey Health, Inc., a medical company, focuses on developing medical products. It develops CardioMap, a heart monitoring and screening device; Save A Life choking rescue devices; and PRV-001 and PRV-002 neurosteroid drug compounds to treat concussions and rare brain disorders. The company was formerly known as Odyssey Group International, Inc. Odyssey Health, Inc. was founded in 2014 and is based in Las Vegas, Nevada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 266.17K | 0.00 | 0.00 | 0.00 | 37.45K | 257.22K | 0.00 |
| Cost of Revenue | 0.00 | 3.42K | 2.37K | 5.55K | 10.52K | 10.55K | 10.55K | 10.55K | 20.30K | 228.49K | 0.00 |
| Gross Profit | 0.00 | -3.42K | -2.37K | -5.55K | 255.64K | -10.55K | -10.55K | -10.55K | 17.15K | 28.73K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 96.05% | 0.00% | 0.00% | 0.00% | 45.80% | 11.17% | 0.00% |
| Research & Development | 55.17K | 201.33K | 1.32M | 9.44M | 20.24K | 23.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.51M | 2.12M | 6.79M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 90.72K | 184.63K | 406.56K |
| Selling & Marketing | 0.00 | 2.82M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.51M | 4.94M | 6.79M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 90.72K | 184.63K | 406.56K |
| Other Expenses | 0.00 | 8.68K | 498.74K | 0.00 | 0.00 | 23.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -14.26M | 5.14M | 8.11M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 90.72K | 184.63K | 406.56K |
| Cost & Expenses | -14.26M | 5.14M | 8.11M | 6.42M | 3.85M | 378.14K | 289.00K | 167.58K | 111.02K | 413.12K | 406.56K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.75K |
| Interest Expense | 518.48K | 614.08K | 836.29K | 1.07M | 502.19K | 70.28K | 62.67K | 30.27K | 12.55K | 4.80K | 0.00 |
| Depreciation & Amortization | 1.54K | 3.42K | 2.37K | 5.55K | 10.52K | 10.55K | 10.55K | 10.55K | 5.14K | 155.90K | 406.56K |
| EBITDA | -2.14M | -5.30M | -7.61M | -6.42M | -3.84M | -23.35M | -409.89K | -157.02K | -68.43K | -155.90K | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,441.25% | 0.00% | 0.00% | 0.00% | -182.71% | -60.61% | 0.00% |
| Operating Income | 14.26M | -5.31M | -8.11M | -15.86M | -3.85M | -378.14K | -420.44K | -167.58K | -73.57K | -155.90K | -406.56K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,445.21% | 0.00% | 0.00% | 0.00% | -196.43% | -60.61% | 0.00% |
| Total Other Income/Expenses | -15.17M | -605.41K | -337.55K | -1.02M | -502.19K | 149.72K | -62.67K | -30.27K | -12.55K | -4.80K | -28.75K |
| Income Before Tax | -905.77K | -5.92M | -8.44M | -16.88M | -4.35M | -448.43K | -483.12K | -197.84K | -86.12K | -160.70K | -435.31K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,633.89% | 0.00% | 0.00% | 0.00% | -229.94% | -62.47% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 337.55K | 1.07M | 502.19K | 70.28K | 131.45K | 30.27K | 12.55K | -155.90K | -28.75K |
| Net Income | -905.77K | -5.92M | -8.78M | -17.96M | -4.85M | -518.71K | -483.12K | -197.84K | -86.12K | -160.70K | -435.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -1,822.56% | 0.00% | 0.00% | 0.00% | -229.94% | -62.47% | 0.00% |
| EPS | -0.01 | -0.07 | -0.10 | -0.19 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.07 | -0.10 | -0.19 | -0.06 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 97.06M | 82.68M | 89.00M | 93.73M | 87.12M | 69.90M | 117.13M | 114.79M | 114.75M | 114.75M | 106.50M |
| Weighted Avg Shares Out (Dil) | 97.06M | 82.68M | 89.00M | 93.73M | 87.12M | 69.90M | 117.13M | 114.79M | 114.75M | 114.75M | 106.50M |
Odyssey Health, Inc. Strengthens Balance Sheet with $8.7 Million in Net Equity
LAS VEGAS, NV / ACCESSWIRE / March 27, 2024 / Odyssey Health, Inc. (OTCQB:ODYY), formerly Odyssey Group International, Inc., (the "Company") a company focused on developing unique, life-enhancing medical products, recently filed its quarterly report for the quarter ended January...
Odyssey Health Closes Asset Sale of its Neurological Drug Technology Pipeline Including Concussion Drug Candidate with Oragenics, Inc.
LAS VEGAS, NV / ACCESSWIRE / January 2, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey" or the "Company") today announces the closing of the definitive Asset Purchase Agreement, that was entered into on October 4, 2023, with Oragenics, Inc., (OGEN:NYSE...
Odyssey Health, Inc. Gains Shareholder Approval for Asset Sale with Oragenics, Inc.
LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. (OTCOB:ODYY), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for the...
Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Concussion
LAS VEGAS, NV / ACCESSWIRE / November 16, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, has selected Syneos Health®, a leading fully integrated biopharmaceutical solutions organization to...
Odyssey Health, Inc. to Provide Company Update and Webcast for Shareholders
LAS VEGAS, NV / ACCESSWIRE / November 15, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), formerly Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, will hold a webcast to provide an update on the Company and...
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.
LAS VEGAS, NV / ACCESSWIRE / October 18, 2023 / Odyssey Health, Inc. (OTCQB:ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products is providing an update on its Asset Purchase Agreement with Oragenics, Inc....
Odyssey Health Inc. Begins Trading on the OTCQB
LAS VEGAS, NV / ACCESSWIRE / October 4, 2023 / Odyssey Health, Inc. (formerly known as Odyssey Group International, Inc. (OTCQB:ODYY) (the "Company" or "Odyssey"), is a medical device and pharmaceutical company with a focus on life-enhancing medical solutions, today...
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
IRVINE, CA, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving medical products, today announced the filing of a provisional patent on its novel...
Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion
IRVINE, CA, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a medical company focused on developing unique, life-saving medical products, today announced successful completion of their clinical trial site initiation visit...
Odyssey Group International Approved to Start Human Trial to Treat Concussion
IRVINE, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC: ODYY ) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced its approval to begin Phase 1 human clinical trials for...
Source: https://incomestatements.info
Category: Stock Reports